| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.8M | -22.8% | -84.2% |
| SG&A Expense | $4.0M | +11.5% | -46.5% |
| Operating Income | -$6.9M | +5.7% | +76.8% |
| Net Income | -$6.6M | +5.1% | +77.0% |
| EPS (Basic) | -$1.68 | -833.3% | -124.0% |
| EPS (Diluted) | -$1.68 | -833.3% | -124.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $20.9M | +5.0% | -69.7% |
| Short-term Investments | $4.4M | -56.2% | — |
| Current Assets | $27.0M | -16.1% | -67.0% |
| Total Assets | $30.0M | -15.5% | -65.2% |
| Current Liabilities | $2.8M | -6.5% | -90.0% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$26.3M | — | — |
| Capital Expenditures | $33K | — | — |
| Investing Cash Flow | -$1.3M | — | — |
| Financing Cash Flow | $24K | — | — |
| Free Cash Flow | -$26.4M | — | — |
| $3.2M |
| -8.8% |
| -88.7% |
| Stockholders' Equity | $26.8M | -16.3% | -53.5% |